These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23834040)

  • 1. Current medical treatment of diabetes type 2 and long term morbidity: how to balance efficacy and safety?
    Carrera Boada CA; Martínez-Moreno JM
    Nutr Hosp; 2013 Mar; 28 Suppl 2():3-13. PubMed ID: 23834040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
    Shaefer CF; Anderson J
    Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased priority for regimens involving incretin-based and insulin therapy.
    Rodbard HW
    J Fam Pract; 2013 Dec; 62(12 Suppl CME):S5-11. PubMed ID: 24340348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
    Niswender K
    Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
    Aronson R
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):603-12. PubMed ID: 24147558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
    Lo MC; Lansang MC
    Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations.
    Blonde L; Dipp S; Cadena D
    Adv Ther; 2018 Jul; 35(7):939-965. PubMed ID: 29777519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents.
    Barnett A
    Int J Clin Pract Suppl; 2007 Aug; (154):12-8. PubMed ID: 17593273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus.
    Brunton SA
    Postgrad Med; 2012 Jul; 124(4):74-83. PubMed ID: 22913896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and tolerability of oral antidiabetes drugs in the treatment of type 2 diabetes mellitus].
    Pedrianes Martín PB; de Pablos Velasco PL
    Med Clin (Barc); 2010 Sep; 135 Suppl 2():20-6. PubMed ID: 21420534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.
    Thompson AM; Linnebur SA; Vande Griend JP; Saseen JJ
    Consult Pharm; 2014 Feb; 29(2):110-23. PubMed ID: 24513421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.